First details of lurasidone's Phase III efficacy in bipolar depression
This article was originally published in Scrip
Executive Summary
The first detailed results from the pivotal clinical trials used to support the US approval earlier this year of Dainippon Sumitomo Pharma's Latuda (lurasidone) in the treatment of bipolar I depression have been published.